- Stallion Uranium Corp. (SUA.V) raised $14M CAD at $0.50/share, targeting a 5,000-metre drill program in Saskatchewan’s Athabasca Basin in Q4 2026.
- NovaMind Health Technologies (NMH.V) raised $10M CAD at $1.25/share, commercializing an AI radiology triage platform already piloted in Quebec hospitals.
- Stallion’s four-month insider lock-up expires mid-December 2026; NovaMind’s six-month lock-up provides stronger near-term downside protection for retail buyers.
- Both deals were supported by established Canadian underwriters — Haywood Securities and Stifel GMP — signalling credible institutional backing for small-cap raises.
Two companies rang the bell on the TSX Venture Exchange this week, offering retail investors early access to a Athabasca Basin uranium play and a Montreal-based AI diagnostics firm — even as the broader TSX Composite slipped 0.82% to 36,368 on August 19, 2026.
Stallion Uranium Corp. (SUA.V) — Uranium Exploration
Stallion Uranium Corp. began trading on the TSX-V on August 18, 2026, under the ticker SUA.V, pricing its IPO at $0.50 per share and raising $14 million CAD through the sale of 28 million shares. The Saskatoon-headquartered company holds four contiguous claim blocks totalling 112,000 hectares in Saskatchewan’s Athabasca Basin — the world’s highest-grade uranium district and home to Cameco’s flagship McArthur River operation. Proceeds are earmarked for a 5,000-metre maiden drill program slated to begin in Q4 2026.
The offering was led by Haywood Securities as sole bookrunner, with PI Financial and Canaccord Genuity participating as co-underwriters — a syndicate lineup that signals meaningful institutional interest for a sub-$20M raise. Haywood placed roughly 60% of the book with institutional accounts, according to the prospectus filing with the British Columbia Securities Commission. Uranium spot prices remain elevated near US$87/lb (approximately CAD $120.70/lb at the current 1.3874 rate), lending fundamental support to the listing.
For retail investors, the story is straightforward: pure-play Athabasca Basin exposure at a sub-dollar entry price. The insider lock-up period is four months from the IPO close date, meaning insiders and seed shareholders — who paid $0.10–$0.15 per share — are free to sell beginning mid-December 2026. That overhang is worth monitoring. The minimum board lot is 500 shares ($250 CAD at IPO price), keeping the position accessible to most self-directed investors. No dividend is expected; this is a pure exploration-stage, growth-oriented holding.
NovaMind Health Technologies (NMH.V) — AI MedTech
NovaMind Health Technologies listed on the TSX-V on August 19, 2026, under ticker NMH.V, pricing at $1.25 per share and raising $10 million CAD via an 8-million-share offering. The Montreal company has built an AI-powered radiology triage platform that integrates with hospital PACS systems to flag critical findings — such as intracranial hemorrhages and pulmonary embolisms — within 60 seconds of image upload. The technology is currently deployed in pilot programs at three Quebec hospital networks, with a commercialization agreement signed with a pan-Canadian health authority expected to be announced in H1 2027.
The deal was underwritten by Stifel GMP as lead, with Echelon Capital Markets as co-underwriter. Approximately 40% of the raise was anchored by two Canadian healthcare-focused venture funds — BDC Capital’s Health Tech Fund and MedBridge Ventures — providing a degree of institutional credibility uncommon for a sub-$15M TSX-V debut. NovaMind generated $1.8 million CAD in recurring software revenue over the trailing twelve months, making it one of the few revenue-positive issuers at this stage on the exchange.
Retail accessibility is moderate: shares priced at $1.25 put a 400-share board lot at $500 CAD. The insider lock-up is six months, expiring in mid-February 2027, longer than the Stallion deal and a positive signal of management conviction. Seed investors paid $0.40 per share, so dilution risk exists but is partially cushioned by the longer restriction period. Investors should review NovaMind’s prospectus carefully for regulatory approval timelines and Health Canada certification requirements before sizing a position.
| Company | Ticker | Exchange | Sector | IPO Price | Funds Raised | Lead Underwriter | Insider Lock-Up |
|---|---|---|---|---|---|---|---|
| Stallion Uranium Corp. | SUA.V | TSX-V | Uranium Exploration | $0.50 CAD | $14M CAD | Haywood Securities | 4 months (mid-Dec 2026) |
| NovaMind Health Technologies | NMH.V | TSX-V | AI / MedTech | $1.25 CAD | $10M CAD | Stifel GMP | 6 months (mid-Feb 2027) |
Both listings arrive on a down day for Canadian equities, which can cut two ways for new issuers: broader weakness may suppress opening-day enthusiasm, but it also tends to filter out purely momentum-driven buyers. Investors considering either name should watch first-week trading volume closely — thin volume on a TSX-V debut is often a more reliable warning signal than the opening price itself.
